Pin1 modulates chemo-resistance by up-regulating FoxM1 and the involvements of Wnt/β-catenin signaling pathway in cervical cancer

Molecular and Cellular Biochemistry

Volumn 413, Issue 1-2, 2016, Pages 179-187

  Wang, Tao ^a   Liu, Zi ^a   Shi, Fan ^a   Wang, Jiquan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Cervical cancer; Chemo resistance; Cisplatin; FoxM1; Pin1

Indexed keywords

BETA CATENIN; CISPLATIN; CYCLIN D1; FOXM1 PROTEIN; MYC PROTEIN; PEPTIDYLPROLYL ISOMERASE PIN1; PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WNT PROTEIN; ANTINEOPLASTIC AGENT; FORKHEAD BOX PROTEIN M1; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; NIMA INTERACTING PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE; PIN1 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; UTERINE CERVIX CANCER; WNT SIGNALING PATHWAY; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; METABOLISM; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FORKHEAD BOX PROTEIN M1; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; NIMA-INTERACTING PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE; UP-REGULATION; UTERINE CERVICAL NEOPLASMS; WNT SIGNALING PATHWAY;

EID: 84957435138     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2651-4     Document Type: Article

References (37)

1. Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy[J]. Nat Rev Cancer 3(7):502–516
2. Fodale V, Pierobon M et al (2011) Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance?[J]. Cancer J 17(2):89–95
3. Fernandez-Luna JL (2008) Regulation of pro-apoptotic BH3-only proteins and its contribution to cancer progression and chemoresistance[J]. Cell Signal 20(11):1921–1926
4. Galluzzi L, Senovilla L et al (2012) Molecular mechanisms of cisplatin resistance[J]. Oncogene 31(15):1869–1883
5. Ryo A, Liou YC et al (2003) Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer[J]. J Cell Sci 116(Pt 5):773–783
6. Lu KP, Suizu F et al (2006) Targeting carcinogenesis: a role for the prolyl isomerase Pin1?[J]. Mol Carcinog 45(6):397–402
7. Bao L, Kimzey A et al (2004) Prevalent overexpression of prolyl isomerase Pin1 in human cancers[J]. Am J Pathol 164(5):1727–1737
8. Ryo A, Uemura H et al (2005) Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer[J]. Clin Cancer Res 11(20):7523–7531
9. Ayala G, Wang D et al (2003) The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer[J]. Cancer Res 63(19):6244–6251
10. Tan X, Zhou F et al (2010) Pin1 expression contributes to lung cancer: prognosis and carcinogenesis[J]. Cancer Biol Ther 9(2):111–119
11. Leung KW, Tsai CH et al (2009) Pin1 overexpression is associated with poor differentiation and survival in oral squamous cell carcinoma[J]. Oncol Rep 21(4):1097–1104
12. Miyashita H, Uchida T et al (2003) Expression status of Pin1 and cyclins in oral squamous cell carcinoma: Pin1 correlates with Cyclin D1 mRNA expression and clinical significance of cyclins[J]. Oncol Rep 10(4):1045–1048
13. Nakashima M, Meirmanov S et al (2004) Cyclin D1 overexpression in thyroid tumours from a radio-contaminated area and its correlation with Pin1 and aberrant beta-catenin expression[J]. J Pathol 202(4):446–455
14. Wang Y, Wen L et al (2013) FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients[J]. Lung Cancer 79(2):173–179
15. Li H, Wang S et al (2006) Pin1 contributes to cervical tumorigenesis by regulating cyclin D1 expression[J]. Oncol Rep 16(3):491–496
16. Kruiswijk F, Hasenfuss SC et al (2015) Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling[J]. Oncogene 1–12
17. Laoukili J, Stahl M et al (2007) FoxM1: at the crossroads of ageing and cancer[J]. Biochim Biophys Acta 1775(1):92–102
18. Koo CY, Muir KW et al (2012) FOXM1: from cancer initiation to progression and treatment[J]. Biochim Biophys Acta 1819(1):28–37
19. Okada K, Fujiwara Y et al (2013) Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer[J]. Ann Surg Oncol 20(3):1035–1043
20. Zhou J, Wang Y et al (2014) FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer[J]. PLoS One 9(5):e96989
21. Kwok JM, Peck B et al (2010) FOXM1 confers acquired cisplatin resistance in breast cancer cells[J]. Mol Cancer Res 8(1):24–34
22. Ding Q, Huo L et al (2008) Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer[J]. Cancer Res 68(15):6109–6117
23. Kim CJ, Cho YG et al (2005) Pin1 overexpression in colorectal cancer and its correlation with aberrant beta-catenin expression[J]. World J Gastroenterol 11(32):5006–5009
24. Zhang N, Wei P et al (2011) FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis[J]. Cancer Cell 20(4):427–442
25. Kruiswijk F, Hasenfuss SE et al (2014) Targeted treatment of metastatic melanoma through interference with Pin1-FOXM1 signaling[J]. Cancer Res 74(19 Supplement):4603
26. Cui J, Jiang W et al (2012) Role of Wnt/beta-catenin signaling in drug resistance of pancreatic cancer[J]. Curr Pharm Des 18(17):2464–2471
27. Arend RC, Londono-Joshi AI et al (2013) The Wnt/beta-catenin pathway in ovarian cancer: a review[J]. Gynecol Oncol 131(3):772–779
28. Yao H, Ashihara E et al (2011) Targeting the Wnt/beta-catenin signaling pathway in human cancers[J]. Expert Opin Ther Targets 15(7):873–887
29. Shen DW, Pouliot LM et al (2012) Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes[J]. Pharmacol Rev 64(3):706–721
30. Lu Z, Hunter T (2014) Prolyl isomerase Pin1 in cancer[J]. Cell Res 24:1033–1049
31. Myatt SS, Lam EW (2007) The emerging roles of forkhead box (Fox) proteins in cancer[J]. Nat Rev Cancer 7(11):847–859
32. Myatt SS, Lam EW (2008) Targeting FOXM1[J]. Nat Rev Cancer 8(3):242
33. Liu Y, Chen X et al (2015) FOXM1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and mediates sensitivity to cisplatin in A549 cells via the JNK/mitochondrial pathway[J]. Neoplasma 62(1):61–71
34. de Keizer P (2009) Regulation of Forkhead BOX O tumor suppressors by Reactive Oxygen Species[M]. Utrecht University Repository
35. Polakis P (2012) Wnt signaling in cancer[J]. Cold Spring Harb Perspect Biol 4:a008052
36. Kahn M (2014) Can we safely target the WNT pathway?[J]. Nat Rev Drug Discov 13(7):513–532
37. Pang R, Yuen J et al (2004) PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma[J]. Oncogene 23(23):4182–4186